Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Blood Cancer Discov
; 5(3): 146-152, 2024 May 01.
Article
in En
| MEDLINE
| ID: mdl-38441243
ABSTRACT
SUMMARY:
While the current approach to precursor hematologic conditions is to "watch and wait," this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit-risk assessment.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Clinical Trials as Topic
/
Multiple Myeloma
Limits:
Humans
Language:
En
Journal:
Blood Cancer Discov
Year:
2024
Document type:
Article
Country of publication: